What Is 3-Methylglutaconic aciduria type 3

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Methylglutaconic aciduria type 3 is a rare autosomal recessive metabolic disorder caused by mutations in the OPA3 gene, primarily associated with optic atrophy and movement disorders. It is also known as Costeff syndrome, first described in 1989 among Iraqi Jewish families with a carrier frequency of about 1 in 10.

Key Facts

3-Methylglutaconic aciduria type 3 is caused by mutations in the OPA3 gene on chromosome 19q13.2-q13.3
First identified in 1989 among Iraqi Jewish families with a carrier rate of ~1 in 10
Inheritance pattern is autosomal recessive, meaning both parents must carry a mutation
More than 20 cases have been reported worldwide, primarily in individuals of Iraqi Jewish descent
Primary symptoms include childhood-onset optic atrophy, spasticity, and movement disorders

Overview

3-Methylglutaconic aciduria type 3, also known as Costeff syndrome, is a rare genetic disorder affecting mitochondrial metabolism. It is characterized by increased urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid, which serve as biochemical markers for the condition.

Primarily observed in individuals of Iraqi Jewish heritage, the disorder manifests in early childhood with progressive neurological and visual impairments. While not life-threatening in all cases, it leads to significant disability over time, particularly due to optic nerve degeneration and motor dysfunction.

Genetic cause: Mutations in the OPA3 gene disrupt mitochondrial function, leading to abnormal organic acid accumulation in urine.
Onset age: Symptoms typically appear between 1 and 5 years old, beginning with vision loss and delayed motor development.
Optic atrophy: Nearly all patients develop bilateral optic atrophy by age 10, resulting in severe visual impairment or blindness.
Movement disorders: Spasticity, ataxia, and dystonia are common, with over 80% of patients developing spastic paraplegia.
Ethnic prevalence: The condition has a high carrier frequency of 1 in 10 among Iraqi Jews, suggesting a founder mutation.

How It Works

The disorder arises from impaired mitochondrial dynamics due to defective OPA3 protein function. This leads to abnormal energy metabolism and increased oxidative stress in neural and retinal tissues.

OPA3 gene: Located on chromosome 19q13.2, this gene encodes a mitochondrial protein involved in membrane fusion and apoptosis regulation.
Mutation types: Two known pathogenic variants—c.433C>T and c.274C>T—are responsible for most cases in the Iraqi Jewish population.
Metabolic byproducts: Defective mitochondria produce excess 3-methylglutaconic acid, detectable in urine via organic acid analysis.
Neurodegeneration: Progressive damage to the optic nerve and basal ganglia leads to vision loss and movement disorders.
Cellular energy: Impaired mitochondrial ATP production affects high-energy tissues like the brain and retina.
Autosomal recessive: A child must inherit two mutated copies of OPA3 (one from each parent) to develop the disease.

Comparison at a Glance

Below is a comparison of 3-methylglutaconic aciduria types 1–3, highlighting key differences in genetics, symptoms, and prevalence:

Type	Gene	Inheritance	Key Symptoms	Prevalence
Type 1	AUH	Autosomal recessive	Mild developmental delay, metabolic acidosis	Rare, global distribution
Type 2	TAZ (G4.5)	X-linked	Barth syndrome: cardiomyopathy, neutropenia	~1 in 200,000 males
Type 3	OPA3	Autosomal recessive	Optic atrophy, spasticity, movement disorders	~1 in 10,000 Iraqi Jews
Type 4	Unknown	Autosomal recessive	Heterogeneous symptoms, includes types 1–3 features	Extremely rare
Type 5	DNM1L	Autosomal dominant	Encephalopathy, seizures, microcephaly	Few reported families

This table illustrates how type 3 differs from other forms, particularly in its genetic cause and ethnic clustering. While types 1 and 2 have broader metabolic or cardiac involvement, type 3 is distinguished by its strong neurological and visual phenotype. The high carrier rate in specific populations allows for targeted screening and genetic counseling.

Why It Matters

Understanding 3-methylglutaconic aciduria type 3 is critical for early diagnosis, family planning, and advancing research on mitochondrial diseases. Though rare, it provides insights into neurodegenerative mechanisms and population genetics.

Early diagnosis: Urinary organic acid screening can detect elevated 3-methylglutaconic acid before severe symptoms arise.
Genetic counseling: Carrier testing in high-risk populations can reduce incidence through informed reproductive choices.
Research value: Studying OPA3 helps scientists understand mitochondrial dynamics in neurodegeneration.
Therapeutic targets: No cure exists, but research into antioxidants and mitochondrial stabilizers is ongoing.
Public health: In Israel, population screening programs have reduced new cases among Iraqi Jewish families.
Differential diagnosis: Distinguishing type 3 from other leukodystrophies prevents misdiagnosis and guides management.

While 3-methylglutaconic aciduria type 3 remains a rare condition, its study underscores the importance of genetic screening and personalized medicine in preventing inherited disorders. Continued research may one day lead to targeted therapies that slow or prevent disease progression.